1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Nanoform Finland Oyj
  6. News
  7. Summary
    NANOFH   FI4000330972

NANOFORM FINLAND OYJ

(NANOFH)
  Report
Delayed Nasdaq Helsinki  -  05/19 11:29:38 am EDT
3.525 EUR   -4.73%
05/10Invitation to Nanoform's Interim Report January-March 2022
AQ
05/04Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of Medicine Developers
CI
05/04Nanoform launches "STARMAP Online" placing AI-power at the fingertips of medicine developers
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nanoform financial calendar for 2022

12/10/2021 | 09:46am EDT

Company Announcement

Nanoform Finland Plc

December 10, 2021

04.45 p.m. Finnish time / 03.45 p.m. Swedish time

Nanoform financial calendar for 2022

Helsinki, Finland - In this company announcement Nanoform provides its financial calendar for 2022, which include the planned publication dates of its financial reports, Annual Report and Annual General Meeting.

Planned publication dates for Nanoform's financial reports in 2022:

  • report for Q4 2021 and full year 2021: 22 February 2022
  • report for Q1 2022: 24 May 2022
  • report for Q2 2022 and half-year 2022: 25 August 2022
  • report for Q3 2022 and January-September 2022: 29 November 2022
  • report for Q4 2022 and full year 2022: 28 February 2023

Nanoform plans to publish its Annual Report for the year 2021, which includes the review by the Board of Directors and the audited annual accounts, latest end of March 2022.

Nanoform's Annual General Meeting 2022 is planned to be held on 12 April 2022.

For further information, please contact:

Albert Hæggström, CFO

albert.haeggstrom@nanoform.com / +358 29 370 0150

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com / +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.

https://news.cision.com/nanoform/r/nanoform-financial-calendar-for-2022,c3469990

https://mb.cision.com/Main/18905/3469990/1508423.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about NANOFORM FINLAND OYJ
05/10Invitation to Nanoform's Interim Report January-March 2022
AQ
05/04Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of ..
CI
05/04Nanoform launches "STARMAP Online" placing AI-power at the fingertips of medicine devel..
AQ
04/12Nanoform Finland Plc - Manager's transactions - Niklas Sandler
AQ
04/12Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland P..
AQ
04/12Share subscriptions based on Nanoform Finland Plc's multiple Stock Option Programs
AQ
04/12Nanoform Finland Elects Members to Audit and Compensation Committee
CI
04/12Resolutions of Nanoform Finland Plc's Annual General Meeting on April 12, 2022
AQ
03/25Nanoform Finland Plc - Manager's transactions - Gonçalo Andrade
AQ
03/24Herantis PharmaAnnounces Successful HER-096 Initial Results with Nanoform Technology
AQ
More news
Financials
Sales 2022 7,35 M 7,78 M 7,78 M
Net income 2022 -18,5 M -19,6 M -19,6 M
Net cash 2022 50,4 M 53,3 M 53,3 M
P/E ratio 2022 -14,1x
Yield 2022 -
Capitalization 276 M 292 M 292 M
EV / Sales 2022 30,7x
EV / Sales 2023 12,3x
Nbr of Employees 125
Free-Float 74,0%
Chart NANOFORM FINLAND OYJ
Duration : Period :
Nanoform Finland Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOFORM FINLAND OYJ
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,53 €
Average target price 9,15 €
Spread / Average Target 160%
EPS Revisions
Managers and Directors
Edward Hæggström Chief Executive Officer
Albert Häggström Chief Financial Officer & Director
Miguel Maria de Oliveira Barreiros Calado Chairman
Niklas Sandler Chief Technology Officer
Gonçalo Nuno N. da Silva Rebelo de Andrade Chief Business Operations
Sector and Competitors
1st jan.Capi. (M$)
NANOFORM FINLAND OYJ-43.77%304
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.65%282 789
ABBVIE INC.12.58%269 361
ELI LILLY AND COMPANY6.87%265 718
ROCHE HOLDING AG-15.26%264 329